Clinigen Group PLC (LSE:CLIN) - Share price


Stock Report

Clinigen Group PLC CLIN

Last Price
GBX594.00

Day Change
-3.50|-0.59%

As of 30/11/2021
09:38:14 GMT | GBX
Minimum 15 Minutes Delay.

Last Close597.50p
Day Range584.50 - 627.50
Mkt Cap796.90Mil
52-Wk Range559.81 - 891.79
Yield %1.27
ISINGB00B89J2419
Volume35,694
P/E20.45
P/S0.02
P/CF0.18

Share Price

Total Returns 29/11/2021

 Chg (%)  
More ...
Clinigen Group PLC-2.53 
FTSE 100 TR GBP-1.47
 
Financials
201920202021
More ...
Income Statement
Turnover456.90466.70523.60
Operating Profit58.0069.6058.50
Net Profit5.2014.2039.70
Reported EPS4.0010.6029.20
Balance Sheet
Current Assets231.30312.70302.70
Non Current Assets834.80829.30762.90
Total Assets1,066.101,142.001,065.60
Current Liabilities243.40203.20172.80
Total Liabilities627.70696.40618.60
Total Equity438.40445.60447.00
Cash Flow
Operating Cash Flow81.9084.5060.80
Net Change in Cash46.8057.10-54.20

Regulatory News

DateAuthor Headline
18/10/2017Samuel Meakin Why Smaller Companies Funds Have Outperformed
The average UK smaller companies fund has comfortably outperformed the FTSE Small Cap and Numis Smaller Companies indices in 2017 so far
06/10/2016Karen Kwok Gold Investors Have Doubled Their Money in 2016
Precious metals, natural resources and Latin American funds are the top performing so far in 2016, data from Morningstar reveals
19/09/2013Holly Cook Feeling Contrary? Take a Bet on These Losers
Are this year's worst performers going to be next year's top trumps?

Company Profile

Clinigen Group PLC is a global pharmaceutical and health-services company that operates in three areas of global medicine supply: clinical trials, unlicensed medicines, and licensed medicines. The vast majority of the company's revenue is derived from unlicensed medicine activities, followed by licensed medicines. The bulk of Clinigen's profit is generated in European regions and the United States. The company maintains a presence in emerging markets around the world, where recent activities have focused on widening customer bases while addressing concerns surrounding counterfeit medicines.

Sector

Medical Distribution

Index

FTSE AIM UK 50 , FTSE AIM 100 , FTSE AIM All-Share

Next Event 23/02/2022

Half-Yearly Results
Ratios
Comp
More ...
PER (E)20.99
Div Yld (E)1.24
PEG (E)0.00
ROCE7.11
Op Mrgn0.11
EPS Grwth0.03
Dividends
PreviousLatest
More ...
Record Date19/03/2103/12/21
Ex-Div18/03/2102/12/21
Paid13/04/2104/01/22
Amnt2.155.46
Directors
More ...
Non-Executive DirectorMs. Anne Philomena Hyland
Non-Executive Director, ChairmanMr. Elmar Schnee
Executive Director, Chief Executive OfficerMr. Shaun Edward Chilton
Non-Executive DirectorProfessor Alan Keith Boyd
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2021 Morningstar. All rights reserved.